Fresenius Kabi Contract Manufacturing
About Fresenius Kabi Contract Manufacturing
Fresenius Kabi Contract Manufacturing Industry Content
Certifications
Categories

-
AT
-
2015On CPHI since
-
4Certificates
-
5000+Employees
Company types
Meet us at
CPHI Frankfurt 2022
Messe Frankfurt, Frankfurt, Germany
1-3 November 2022
Fresenius Kabi Contract Manufacturing Resources (6)
-
News Fresenius Kabi invests in Pre-Filled Syringe Capacities for US and EU supply
As a safe, effective and convenient way to administer injectable medications, pre-filled syringes (PFS) have become the injection system of choice for a growing number of drugs. PFS allow healthcare professionals to easily handle syringes, reduce waste and save time by providing a ready-to-use container, while also allowing them to precisely dose and minimize overfill. -
Brochure Fresenius Kabi Contract Manufacturing Brochure
Find out about our Contract Manufacturing and fill- and finishing services for sterile pharmaceuticals and medical devices. We offer different containers in various sizes like pre-filled syringes, ampoules, vials, bottles and IV-bags. -
Brochure INSIGHT US
In our latest INSIGHT edition we introduce our three US facilities and our new US team. -
Brochure INSIGHT IV-bags and medical devices
This INSIGHT edition sheds light on our production site in Halden, Norway, our IV-bag capabilities and our medical devices expertise. -
Video Your Partner for Diluents
As a specialist in diluent solutions Fresenius Kabi is the right partner for you. We offer solutions, that fit together with your needs. Find out more about our diluent production in this video -
Webinar Be Prepared! Combination Products under MDR - Article 117
This extremely topical webinar addresses the challenge that the complex European Medical Device Regulation (MDR) poses for the entire industry, with a special focus on drug combination products and the requirements of Article 117.
Join Heinrich Martens, Vice Regulatory Affairs, Fresenius Kabi and Jonas Orf, Junior Key Account Manager, Fresenius Kabi as they shed light on the new requirements of MDR including stricter pre-market control, oversight of notified bodies, inclusion of products without medical purpose and rules on clinical data and clinical investigations.
They also provide an introduction to the drug combination ‘world’ within the context of MDR Article 117, the role of the Notified Body, fulfilment of the General Safety and Performance Requirements (GSPRs) and responsibilities and obligations of the manufacturer(s).
“In the MDD world that we had in the past, we had the essential requirements, which were similar to the GSPRs, but there was never anything about a Notified Body opinion, an additional approval step for the device that was required for a drug combination submission to the authority,” says Martens. “Which is totally different when you look now into Article 117.”
By watching this webinar, you will understand:
What is a combination product
The meaning of Article 117
The role and task of the Notified Body
Manufacturer responsibilities
Evidence and fulfilment of the GSPRs
Notified Body opinion
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance